Ciclesonide

Ciclesonide
Clinical data
Trade names	Omnaris, others
Other names	(11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
AHFS/Drugs.com	Monograph
MedlinePlus	a607008
Pregnancy; category	AU: B3; ;
Routes of; administration	Nasal inhalation
ATC code	R01AD13 (WHO) R03BA08 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate;
CAS Number	126544-47-6 ;
PubChem CID	6918155;
IUPHAR/BPS	7469;
DrugBank	DB01410 ;
ChemSpider	5293368 ;
UNII	S59502J185;
KEGG	D01703 ;
ChEMBL	ChEMBL1201164 ;
CompTox Dashboard (EPA)	DTXSID9046659 ;
ECHA InfoCard	100.210.908
Chemical and physical data
Formula	C32H44O7
Molar mass	540.697 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]25O[C@@H](O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C6CCCCC6)C(C)C;
	InChI InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 ; Key:LUKZNWIVRBCLON-GXOBDPJESA-N ;
	(what is this?) (verify)

Ciclesonide, sold under the brand name Omnaris among others, is a glucocorticoid used to treat asthma and allergic rhinitis.

Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.^[6]

It was patented in 1990 and approved for medical use in 2005.^[7] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.^[8] It is on the World Health Organization's List of Essential Medicines.^[9]

Society and culture

It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.

^ "Omnaris- ciclesonide spray". DailyMed. 8 November 2022. Retrieved 29 June 2024.
^ "Alvesco- ciclesonide aerosol, metered". DailyMed. 16 February 2023. Retrieved 29 June 2024.
^ "Zetonna- ciclesonide aerosol, metered". DailyMed. 16 February 2023. Retrieved 29 June 2024.
^ "Aservo Equihaler- ciclesonide spray, metered". DailyMed. 16 September 2021. Retrieved 29 June 2024.
^ "Aservo Equihaler EPAR". European Medicines Agency. 28 February 2020. Retrieved 29 June 2024.
^ Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–1664. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
^ "FDA News Release. FDA Approves New Treatment for Allergies". Food and Drug Administration. 23 October 2006. Archived from the original on 9 July 2009. Retrieved 30 July 2009.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.